Cargando…

BiTE secretion from in situ-programmed myeloid cells results in tumor-retained pharmacology

Bispecific T-Cell Engagers (BiTEs) are effective at inducing remission in hematologic cancers, but their use in solid tumors has been challenging due to their extreme potency and on-target, off-tumor toxicities in healthy tissue. Their deployment against solid tumors is further complicated by insuff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hao, S., Inamdar, V.V., Sigmund, E.C., Zhang, F., Stephan, S.B., Watson, C., Weaver, S.J., Nielsen, U.B., Stephan, M.T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8840964/ https://www.ncbi.nlm.nih.gov/pubmed/34953983 http://dx.doi.org/10.1016/j.jconrel.2021.12.029

Ejemplares similares

Genetic in situ engineering of myeloid regulatory cells controls inflammation in autoimmunity
por: Parayath, N.N., et al.
Publicado: (2021)

Characterization of Magnetron Sputtered BiTe-Based Thermoelectric Thin Films
por: Zhang, Zhenxue, et al.
Publicado: (2023)

T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330
por: Laszlo, G S, et al.
Publicado: (2015)

Development and characterization of in-situ gel for ophthalmic formulation containing ciprofloxacin hydrochloride
por: Makwana, S.B., et al.
Publicado: (2015)

Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
por: Kegyes, David, et al.
Publicado: (2022)

BiTE‐Secreting CAR‐γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors
por: Huang, Shi‐Wei, et al.
Publicado: (2023)

Immunotherapy using bispecific T cell engager (BiTE(®)) antibodies: preclinical and clinical experience in acute leukemia
por: Subklewe, Marion, et al.
Publicado: (2014)

Bispecific T cell engager (BiTE(®)) antibody constructs can mediate bystander tumor cell killing
por: Ross, Sandra L., et al.
Publicado: (2017)

Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma
por: Li, Gaowei, et al.
Publicado: (2021)

Formation of Fe-Te Nanostructures during in Situ Fe Heavy Doping of Bi(2)Te(3)
por: Liang, Jing, et al.
Publicado: (2019)

Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas
por: Arnone, Claudia Manuela, et al.
Publicado: (2021)

BiTE secretion by adoptively transferred stem-like T cells improves FRα+ ovarian cancer control
por: McGray, A J Robert, et al.
Publicado: (2023)

Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy
por: Yang, Xiao-mei, et al.
Publicado: (2023)

CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
por: Jitschin, Regina, et al.
Publicado: (2018)

A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
por: Brey, Charlotte U., et al.
Publicado: (2018)

Correction: Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas
Publicado: (2021)

Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications
por: Hoffman, Lindsey M., et al.
Publicado: (2014)

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk
por: Harrington, Kimberly H., et al.
Publicado: (2015)

Electronic Structure and Transport Properties of Bi(2)Te(3) and Bi(2)Se(3) Single Crystals
por: Marchenkov, Vyacheslav V., et al.
Publicado: (2023)

Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathway
por: Shen, Ye, et al.
Publicado: (2022)

Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond
por: Epperly, Rebecca, et al.
Publicado: (2020)

Novel Immune Engagers and Cellular Therapies for Metastatic Castration-Resistant Prostate Cancer: Do we take a BiTe or ride BiKEs, TriKEs, and CARs?
por: Zorko, Nicholas A., et al.
Publicado: (2021)

CAR-T cells and BiTEs in solid tumors: challenges and perspectives
por: Edeline, Julien, et al.
Publicado: (2021)

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
por: Wu, Jingjing, et al.
Publicado: (2015)

Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies Against Extranodal Nasal Natural Killer/T Cell Lymphoma
por: Zheng, Meijun, et al.
Publicado: (2020)

Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy
por: Maruta, Masaki, et al.
Publicado: (2019)

Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy
por: Khalique, Hena, et al.
Publicado: (2021)

CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma
por: Lei, Wen, et al.
Publicado: (2022)

In-situ Observation of Size and Irradiation Effects on Thermoelectric Properties of Bi-Sb-Te Nanowire in FIB Trimming
por: Chien, Chia-Hua, et al.
Publicado: (2016)

Room temperature in-situ measurement of the spin voltage of a BiSbTe(3) thin film
por: Leis, Arthur, et al.
Publicado: (2020)

ZnSe/ZnSeTe Superlattice Nanotips
por: Hsiao, CH, et al.
Publicado: (2010)

Bi(2)Te(3) Thin Films Deposited by the Combination of Bi and Te Plasmas in a PLD Process
por: Reyes-Verdugo, Laura A., et al.
Publicado: (2023)

Simultaneous Multiple Interaction T-cell Engaging (SMITE) Bispecific Antibodies Overcome Bispecific T-cell Engager (BiTE) Resistance Via CD28 Co-Stimulation
por: Correnti, Colin E., et al.
Publicado: (2018)

Factors Associated With Bites to a Child From a Dog Living in the Same Home: A Bi-National Comparison
por: Messam, Locksley L. McV., et al.
Publicado: (2018)

Woodchuck Hepatitis Virus Post-Transcriptional Regulation Element (WPRE) Promotes Anti-CD19 BiTE Expression in Expi293 Cells
por: Moazzami, Reza, et al.
Publicado: (2021)

Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer
por: Wang, Qiuman, et al.
Publicado: (2022)

BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?
por: Allen, Cecily, et al.
Publicado: (2021)

Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
por: Wathikthinnakon, Methi, et al.
Publicado: (2022)

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
por: Ferrari, Francesca, et al.
Publicado: (2015)

Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients
por: Abid, Muhammad Bilal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_em7lfnspr2qdfp8hnch3hgtqcb